Drug intelligence / Profile preview

VOLT-02

Development stage: Unknown
Lead developer: Levolta Pharmaceuticals
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration: Parenteral

Overview

VOLT-02 is a water-soluble conjugate of progesterone and a neurosteroid under development by Levolta Pharmaceuticals for the treatment of traumatic brain injury, gynecological disorders, and menstrual disorders. It acts as a progestogen and neurosteroid, with its primary mechanism being agonism at the progesterone receptor. As of March 2017, it was in phase II clinical trials for these indications. The precise chemical structure has not been publicly disclosed[1][2].

Other names: Progesterone conjugate

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on VOLT-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VOLT-02.

Explore the full profile